CA-AFFINITY
16.6.2022 12:02:09 CEST | Business Wire | Press release
Affinity , the relationship intelligence platform for dealmakers, and Dealroom.co, a global provider of data and intelligence on startups and tech ecosystems, today announced a partnership to provide the most powerful combination of predictive intelligence and relationship intelligence for dealmakers. The partnership will provide Affinity clients with additional data intelligence for over 1.7 million startups and 2.1 million organizations globally. Joint clients of both Affinity and Dealroom.co will be able to access even more insights through additional data columns.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005042/en/
“Our clients use Affinity to find, manage, and close the most important deals, and using organizational data insights helps them to target the right organizations is a critical part of their success,“ said Ray Zhou , CEO of Affinity. “Adding Dealroom.co’s predictive intelligence data to Affinity will ensure they can do that faster and with more confidence than ever before. ”
Affinity’s platform will integrate Dealroom.co’s wide range of critical data to enrich organizational records with additional firmographic data, predictive data insights, and leading market momentum indicators (such as social engagement). This will enable investors, M&A professionals, and other dealmakers to deliver the most complete understanding of deal opportunities and reduce the time they spend deciding which deals or organizations to focus on. Joint clients of both organizations will also receive access to additional Dealroom.co data columns in Affinity, including app downloads, website traffic, and founders’ history of success, further streamlining organizational intelligence gathering.
“As the intelligence layer for tech ecosystems, we help clients discover the world’s most promising companies through predictive intelligence,” said Yoram Wijngaarde , Founder and CEO at Dealroom.co. “This partnership puts this timely data into the hands of more investors around the world. We're excited to work with Affinity to provide investors with the data they need to be successful.”
Learn more about the power of Affinity and Dealroom.co’s data in the recently released joint report “Relationship Intelligence Benchmark Report: European Unicorn Edition ,” and watch the “European Unicorn Trends: How to Make Unicorn Hunting More Predictable ” webinar which brings industry experts together to discuss the trends impacting dealmakers as well as the role relationship intelligence plays in the evolving market landscape.
Across the Affinity platform, over 500,000 new introductions are made and 450,000 deals are managed per month, helping dealmakers to find, manage, and close more deals. Currently, Affinity serves over 2,000 clients worldwide, including 500 in Europe where many already use Dealroom.co data in their dealmaking process. By capturing the exhaust of relationship interactions—over 18 trillion emails and 213 million calendar invites to date—Affinity automates the creation of contact and company records and tracks activity saving over 220 hours every year in data entry work.
About Affinity
Affinity is a relationship intelligence platform that empowers dealmakers in relationship-driven industries to find, manage and close more deals. With the most automated relationship intelligence insights and technology, Affinity enables leaders to drive deals, free themselves from data drudgery and ensure their teams can take action with confidence, knowing the context and history of every relationship. The Affinity platform, including Affinity CRM, is used by over 2,000 relationship-driven organizations around the world. Founded in 2014, Affinity is headquartered in San Francisco and backed by leading investors including Menlo Ventures, Advance Venture Partners, 8VC and MassMutual Ventures.
About Dealroom.co
Dealroom.co is the foremost data provider on startups, innovation, high-growth companies,
ecosystems, and emerging tech. Founded in Amsterdam in 2013, Dealroom.co works with many of the world’s most prominent investors, entrepreneurs, and government organizations to provide transparency, analysis, and insights on venture capital activity. Dealroom.co mission is to accelerate entrepreneurship and innovation through data, insights, and predictive intelligence.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom